88.26
3.87 (4.59%)
| Penutupan Terdahulu | 84.39 |
| Buka | 84.80 |
| Jumlah Dagangan | 87,619 |
| Purata Dagangan (3B) | 146,049 |
| Modal Pasaran | 625,643,264 |
| Harga / Buku (P/B) | 14.87 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 22 Dec 2025 |
| EPS Cair (TTM) | -0.400 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.30% |
| Nisbah Semasa (MRQ) | 88.27 |
| Aliran Tunai Operasi (OCF TTM) | -4.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.40 M |
| Pulangan Atas Aset (ROA TTM) | -10.57% |
| Pulangan Atas Ekuiti (ROE TTM) | -11.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Bright Minds Biosciences Inc. | Menurun | - |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.38 |
|
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 22.55% |
| % Dimiliki oleh Institusi | 74.12% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Acuta Capital Partners, Llc | 30 Sep 2025 | 84,875 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Nov 2025 | Pengumuman | Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting |
| 17 Nov 2025 | Pengumuman | Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) |
| 06 Nov 2025 | Pengumuman | Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH |
| 30 Oct 2025 | Pengumuman | Bright Minds Biosciences to Present at Upcoming Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |